{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T14:23:15Z","timestamp":1782310995677,"version":"3.54.5"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T00:00:00Z","timestamp":1503619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s00520-017-3842-1","type":"journal-article","created":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T04:24:02Z","timestamp":1503635042000},"page":"3295-3304","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations"],"prefix":"10.1007","volume":"25","author":[{"given":"Matti","family":"Aapro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Boccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Camps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Campone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Choquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Danova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Glaspy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Hus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thamer","family":"Sliwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Tesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Valero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,25]]},"reference":[{"issue":"1","key":"3842_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8\u201332. doi: 10.1016\/j.ejca.2010.10.013","journal-title":"Eur J Cancer"},{"issue":"suppl 5","key":"3842_CR2","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, Herrstedt J, Committee EG (2016) Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol 27(suppl 5):v111\u2013v118. doi: 10.1093\/annonc\/mdw325","journal-title":"Ann Oncol"},{"issue":"4","key":"3842_CR3","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/cid\/ciq147","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad RKV II, Young JA, Wingard JR, Infectious Diseases Society of A (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52(4):427\u2013431. doi: 10.1093\/cid\/ciq147","journal-title":"Clin Infect Dis"},{"issue":"11","key":"3842_CR4","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1007\/s00520-015-2686-9","volume":"23","author":"Li Wang","year":"2015","unstructured":"Wang L, Baser O, Kutikova L, Page JH, Barron R (2015) The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer. doi: 10.1007\/s00520-015-2686-9","journal-title":"Supportive Care in Cancer"},{"issue":"9","key":"3842_CR5","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1002\/cncr.20983","volume":"103","author":"V Caggiano","year":"2005","unstructured":"Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT (2005) Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 103(9):1916\u20131924. doi: 10.1002\/cncr.20983","journal-title":"Cancer"},{"issue":"4","key":"3842_CR6","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/annonc\/mdv619","volume":"27","author":"J. Truong","year":"2015","unstructured":"Truong J, Lee EK, Trudeau ME, Chan KK (2015) Interpreting febrile neutropenia rates from randomized controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis. Ann Oncol 27(4):608-618. doi: 10.1093\/annonc\/mdv619","journal-title":"Annals of Oncology"},{"issue":"2","key":"3842_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.6004\/jnccn.2008.0012","volume":"6","author":"J Crawford","year":"2008","unstructured":"Crawford J, Dale DC, Kuderer NM, Culakova E, Poniewierski MS, Wolff D, Lyman GH (2008) Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Cancer Netw 6(2):109\u2013118","journal-title":"J Natl Compr Cancer Netw"},{"issue":"6","key":"3842_CR8","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1200\/JOP.2015.006742","volume":"11","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Armitage JO (2015) Recommendations for the use of white blood cell growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Oncol Pract 11(6):511\u2013513. doi: 10.1200\/JOP.2015.006742","journal-title":"J Oncol Pract"},{"key":"3842_CR9","doi-asserted-by":"publisher","unstructured":"Leonard RC, Mansi JL, Keerie C, Yellowlees A, Crawford S, Benstead K, Matthew R, Adamson D, Chan S, Grieve R, Anglo-Celtic Collaborative Oncology G (2015) A randomised trial of secondary prophylaxis using granulocyte colony-stimulating factor ('SPROG' trial) for maintaining dose intensity of standard adjuvant chemotherapy for breast cancer by the Anglo-Celtic Cooperative Group and NCRN. Ann Oncol 26(12):2437\u20132441. doi: 10.1093\/annonc\/mdv389","DOI":"10.1093\/annonc\/mdv389"},{"issue":"S1","key":"3842_CR10","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1038\/sj.bjc.6605269","volume":"101","author":"S Kelly","year":"2009","unstructured":"Kelly S, Wheatley D (2009) Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors. Br J Cancer 101(Suppl 1):S6\u201310. doi: 10.1038\/sj.bjc.6605269","journal-title":"British Journal of Cancer"},{"issue":"6","key":"3842_CR11","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1002\/cam4.344","volume":"3","author":"Gisoo Barnes","year":"2014","unstructured":"Barnes G, Pathak A, Schwartzberg L (2014) G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use. Cancer Med 3(6):1477\u20131484. doi: 10.1002\/cam4.344","journal-title":"Cancer Medicine"},{"issue":"1","key":"3842_CR12","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00520-015-2779-5","volume":"24","author":"Hartmut Link","year":"2015","unstructured":"Link H, Nietsch J, Kerkmann M, Ortner P, Supportive Care Group of the German Cancer S (2016) Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy-a representative sample survey in Germany. Support Care Cancer 24(1):367\u2013376. doi: 10.1007\/s00520-015-2779-5","journal-title":"Supportive Care in Cancer"},{"issue":"3","key":"3842_CR13","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1345\/aph.1G516","volume":"40","author":"Derek Weycker","year":"2006","unstructured":"Weycker D, Hackett J, Edelsberg JS, Oster G, Glass AG (2006) Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 40(3):402\u2013407. doi: 10.1345\/aph.1G516","journal-title":"Annals of Pharmacotherapy"},{"key":"3842_CR14","unstructured":"Amgen Ltd (2015) Neulasta\u00ae summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000420\/WC500025945.pdf . Accessed 1 March 2017"},{"key":"3842_CR15","unstructured":"Teva Pharma B.V. (2015) Lonquex\u00ae summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002556\/WC500148380.pdf . Accessed 30 March 2017"},{"issue":"6","key":"3842_CR16","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","volume":"23","author":"Charles L. Vogel","year":"2005","unstructured":"Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, Neumann TA, Schwartzberg LS (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23(6):1178\u20131184. doi: 10.1200\/jco.2005.09.102","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"3842_CR17","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00520-006-0201-z","volume":"15","author":"Ulrich J. M. Mey","year":"2007","unstructured":"Mey UJ, Maier A, Schmidt-Wolf IG, Ziske C, Forstbauer H, Banat GA, Reber M, Strehl JW, Gorschlueter M (2007) Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma. Support Care Cancer 15(7):877\u2013884. doi: 10.1007\/s00520-006-0201-z","journal-title":"Supportive Care in Cancer"},{"issue":"2","key":"3842_CR18","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/j.1365-2354.2008.01004.x","volume":"19","author":"L. MONTELLA","year":"2010","unstructured":"Montella L, Addeo R, Guarrasi R, Cennamo G, Faiola V, Capasso E, Caraglia M, Del Prete S (2010) Once-per-cycle pegfilgrastim in breast cancer patients treated with docetaxel\/epidoxorubicin\/cyclophosphamide. Eur J Cancer Care (Engl) 19(2):200\u2013204. doi: 10.1111\/j.1365-2354.2008.01004.x","journal-title":"European Journal of Cancer Care"},{"issue":"4","key":"3842_CR19","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1634\/theoncologist.12-4-484","volume":"12","author":"H. Ozer","year":"2007","unstructured":"Ozer H, Mirtsching B, Rader M, Luedke S, Noga SJ, Ding B, Dreiling L (2007) Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use. Oncologist 12(4):484\u2013494. doi: 10.1634\/theoncologist.12-4-484","journal-title":"The Oncologist"},{"issue":"3","key":"3842_CR20","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1080\/10428190500305802","volume":"47","author":"Barbara Pro","year":"2006","unstructured":"Pro B, Fayad L, McLaughlin P, Romaguera J, Hagemeister FB, Rodriguez MA, Goy A, Loyer E, Younes A (2006) Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 47(3):481\u2013485. doi: 10.1080\/10428190500305802","journal-title":"Leukemia & Lymphoma"},{"key":"3842_CR21","unstructured":"European Commission (2013) Consensus information paper: what you need to know about biosimilar medicinal products. http:\/\/www.medicinesforeurope.com\/wp-content\/uploads\/2016\/03\/biosimilars_report_en.pdf . Accessed 30 March 2017"},{"issue":"10","key":"3842_CR22","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1007\/s00520-013-1911-7","volume":"21","author":"Pere Gasc\u00f3n","year":"2013","unstructured":"Gascon P, Tesch H, Verpoort K, Rosati MS, Salesi N, Agrawal S, Wilking N, Barker H, Muenzberg M, Turner M (2013) Clinical experience with Zarzio\u00ae in Europe: what have we learned? Support Care Cancer 21(10):2925\u20132932. doi: 10.1007\/s00520-013-1911-7","journal-title":"Supportive Care in Cancer"},{"issue":"7","key":"3842_CR23","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1517\/14712598.2014.905537","volume":"14","author":"Karl Welte","year":"2014","unstructured":"Welte K (2014) G-CSF: filgrastim, lenograstim and biosimilars. Expert Opin Biol Ther 14(7):983\u2013993. doi: 10.1517\/14712598.2014.905537","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"2","key":"3842_CR24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.5639\/gabij.2013.0202.023","volume":"2","author":"Matti Aapro","year":"2013","unstructured":"Aapro M (2013) Biosimilars in oncology: current and future perspectives. Generics and Biosimilars Initiative Journal 2(2):91\u201393","journal-title":"Generics and Biosimilars Initiative Journal"},{"key":"3842_CR25","unstructured":"Hsu CS, Sandford BA (2007) The Delphi technique: making sense of consensus. Pract Assess Res Eval 12(10):1\u20138"},{"issue":"7","key":"3842_CR26","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1001\/jamainternmed.2013.2921","volume":"173","author":"Jason D. Wright","year":"2013","unstructured":"Wright JD, Neugut AI, Ananth CV, Lewin SN, Wilde ET, Lu YS, Herzog TJ, Hershman DL (2013) Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes. JAMA Intern Med 173(7):559\u2013568. doi: 10.1001\/jamainternmed.2013.2921","journal-title":"JAMA Internal Medicine"},{"issue":"12","key":"3842_CR27","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/jnci\/djr152","volume":"103","author":"A. L. Potosky","year":"2011","unstructured":"Potosky AL, Malin JL, Kim B, Chrischilles EA, Makgoeng SB, Howlader N, Weeks JC (2011) Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes. J Natl Cancer Inst 103(12):979\u2013982. doi: 10.1093\/jnci\/djr152","journal-title":"JNCI Journal of the National Cancer Institute"},{"key":"3842_CR28","unstructured":"Lyman GH (2006) Chemotherapy dose intensity and quality cancer care. Oncology (Williston Park) 20(14 Suppl 9):16\u201325"},{"key":"3842_CR29","unstructured":"German Guideline Program in Oncology (2016) S3-Leitlinie Supportive Therapie bei onkologischen PatientInnen. Leitlinienprogramm Onkologie. http:\/\/leitlinienprogramm-onkologie.de\/Supportive-Therapie.95.0.html . Accessed 27 March 2017"},{"issue":"1","key":"3842_CR30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/annonc\/mdg019","volume":"14","author":"M. D. Green","year":"2003","unstructured":"Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14(1):29\u201335","journal-title":"Annals of Oncology"},{"issue":"9","key":"3842_CR31","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1080\/1042819031000103953","volume":"44","author":"Andrew Grigg","year":"2003","unstructured":"Grigg A, Solal-Celigny P, Hoskin P, Taylor K, McMillan A, Forstpointner R, Bacon P, Renwick J, Hiddemann W (2003) Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 44(9):1503\u20131508. doi: 10.1080\/1042819031000103953","journal-title":"Leukemia & Lymphoma"},{"issue":"6","key":"3842_CR32","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/annonc\/mdf130","volume":"13","author":"F. A. Holmes","year":"2002","unstructured":"Holmes FA, Jones SE, O'Shaughnessy J, Vukelja S, George T, Savin M, Richards D, Glaspy J, Meza L, Cohen G, Dhami M, Budman DR, Hackett J, Brassard M, Yang BB, Liang BC (2002) Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 13(6):903\u2013909","journal-title":"Annals of Oncology"},{"issue":"3","key":"3842_CR33","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1200\/JCO.2002.20.3.727","volume":"20","author":"F.A. Holmes","year":"2002","unstructured":"Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I, Neumann TA, Hill LR, Liang BC (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III\/IV breast cancer. J Clin Oncol 20(3):727\u2013731","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"3842_CR34","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1200\/JCO.2003.03.040","volume":"21","author":"J.M. Vose","year":"2003","unstructured":"Vose JM, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J, Frankel S, Flinn I, Lovelace W, Hackett J, Liang BC (2003) Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 21(3):514\u2013519","journal-title":"Journal of Clinical Oncology"},{"key":"3842_CR35","doi-asserted-by":"publisher","unstructured":"Zhang W, Jiang Z, Wang L, Li C, Xia J (2015) An open-label, randomized, multicenter dose-finding study of once-per-cycle pegfilgrastim versus daily filgrastim in Chinese breast cancer patients receiving TAC chemotherapy. Med Oncol 32(5):147. doi: 10.1007\/s12032-015-0537-7","DOI":"10.1007\/s12032-015-0537-7"},{"issue":"2 Supp A","key":"3842_CR36","doi-asserted-by":"publisher","first-page":"10","DOI":"10.18553\/jmcp.2003.9.s2.10","volume":"9","author":"John W. Mucenski","year":"2003","unstructured":"Mucenski JW, Shogan JE (2003) Maximizing the outcomes in cancer patients receiving chemotherapy through optimal use of colony-stimulating factor. J Manag Care Pharm 9(2 Suppl):10\u201314","journal-title":"Journal of Managed Care Pharmacy"},{"key":"3842_CR37","doi-asserted-by":"publisher","unstructured":"Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL (2011) Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 11:404. doi: 10.1186\/1471-2407-11-404","DOI":"10.1186\/1471-2407-11-404"},{"issue":"9","key":"3842_CR38","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1185\/030079907X219599","volume":"23","author":"Lionel Pinto","year":"2007","unstructured":"Pinto L, Liu Z, Doan Q, Bernal M, Dubois R, Lyman G (2007) Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin 23(9):2283\u20132295. doi: 10.1185\/030079907x219599","journal-title":"Current Medical Research and Opinion"},{"issue":"5","key":"3842_CR39","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/cncr.22892","volume":"110","author":"NM Kuderer","year":"2007","unstructured":"Kuderer NM, Khorana AA, Lyman GH, Francis CW (2007) A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer 110(5):1149\u20131161. doi: 10.1002\/cncr.22892","journal-title":"Cancer"},{"issue":"3","key":"3842_CR40","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/ecc.12043","volume":"22","author":"D Almenar Cubells","year":"2013","unstructured":"Almenar Cubells D, Bosch Roig C, Jimenez Orozco E, Alvarez R, Cuervo JM, Diaz Fernandez N, Sanchez Heras AB, Galan Brotons A, Giner Marco V, Codes MDVM (2013) Effectiveness of daily versus non-daily granulocyte colony-stimulating factors in patients with solid tumours undergoing chemotherapy: a multivariate analysis of data from current practice. Eur J Cancer Care (Engl) 22(3):400\u2013412. doi: 10.1111\/ecc.12043","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"3","key":"3842_CR41","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/j.1365-2354.2008.00959.x","volume":"18","author":"D Almenar","year":"2009","unstructured":"Almenar D, Mayans J, Juan O, Bueno JM, Lopez JI, Frau A, Guinot M, Cerezuela P, Buscalla EG, Gasquet JA, Sanchez J (2009) Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain\u2014results of the LEARN Study. Eur J Cancer Care (Engl) 18(3):280\u2013286. doi: 10.1111\/j.1365-2354.2008.00959.x","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"2","key":"3842_CR42","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00520-015-2861-z","volume":"24","author":"Pere Gasc\u00f3n","year":"2015","unstructured":"Gascon P, Aapro M, Ludwig H, Bokemeyer C, Boccadoro M, Turner M, Denhaerynck K, MacDonald K, Abraham I (2015) Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study). Support Care Cancer. doi: 10.1007\/s00520-015-2861-z","journal-title":"Supportive Care in Cancer"},{"key":"3842_CR43","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1471-2407-13-11","volume":"13","author":"A Naeim","year":"2013","unstructured":"Naeim A, Henk HJ, Becker L, Chia V, Badre S, Li X, Deeter R (2013) Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF). BMC Cancer 13:11. doi: 10.1186\/1471-2407-13-11","journal-title":"BMC Cancer"},{"issue":"5","key":"3842_CR44","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.clinthera.2009.05.019","volume":"31","author":"D Weycker","year":"2009","unstructured":"Weycker D, Malin J, Kim J, Barron R, Edelsberg J, Kartashov A, Oster G (2009) Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study. Clin Ther 31(5):1069\u20131081. doi: 10.1016\/j.clinthera.2009.05.019","journal-title":"Clin Ther"},{"issue":"13","key":"3842_CR45","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1016\/j.ejca.2010.04.031","volume":"46","author":"C Falandry","year":"2010","unstructured":"Falandry C, Campone M, Cartron G, Guerin D, Freyer G (2010) Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines. Eur J Cancer 46(13):2389\u20132398. doi: 10.1016\/j.ejca.2010.04.031","journal-title":"Eur J Cancer"},{"issue":"1","key":"3842_CR46","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JOP.2014.001492","volume":"11","author":"Derek Weycker","year":"2015","unstructured":"Weycker D, Li X, Edelsberg J, Barron R, Kartashov A, Xu H, Lyman GH (2014) Risk and consequences of chemotherapy-induced febrile neutropenia in patients with metastatic solid tumors. J Oncol Pract. doi: 10.1200\/JOP.2014.001492","journal-title":"Journal of Oncology Practice"},{"key":"3842_CR47","unstructured":"Amgen Ltd (2015) Neupogen\u00ae summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000917\/WC500046525.pdf . Accessed 27 March 2017"},{"key":"3842_CR48","unstructured":"Sandoz (2015) Filgrastim HEXAL\u00ae summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000726\/WC500028282.pdf . Accessed 30 March 2017"},{"issue":"4","key":"3842_CR49","doi-asserted-by":"crossref","first-page":"337","DOI":"10.18553\/jmcp.2007.13.4.337","volume":"13","author":"VA Morrison","year":"2007","unstructured":"Morrison VA, Wong M, Hershman D, Campos LT, Ding B, Malin J (2007) Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4\u00a0week chemotherapy regimens in community oncology practices. J Manag Care Pharm 13(4):337\u2013348","journal-title":"J Manag Care Pharm"},{"issue":"2","key":"3842_CR50","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/annonc\/mdm438","volume":"19","author":"G Minckwitz von","year":"2008","unstructured":"von Minckwitz G, Kummel S, du Bois A, Eiermann W, Eidtmann H, Gerber B, Hilfrich J, Huober J, Costa SD, Jackisch C, Grasshoff ST, Vescia S, Skacel T, Loibl S, Mehta KM, Kaufmann M (2008) Pegfilgrastim +\/\u2212 ciprofloxacin for primary prophylaxis with TAC (docetaxel\/doxorubicin\/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol 19(2):292\u2013298. doi: 10.1093\/annonc\/mdm438","journal-title":"Ann Oncol"},{"key":"3842_CR51","doi-asserted-by":"crossref","unstructured":"Kim E, Jin R, Choi K, Frankel PH, Somlo G (2010) Safety and efficacy of low-dose pegfilgrastim (pegfil) in maintaining chemotherapy (CT) dose density in patients (pts) receiving docetaxel\/doxorubicin\/cyclophosphamide (TAC) or doxorubicin\/cyclophosphamide (AC) as neoadjuvant chemotherapy (NCT) for stage II-III breast cancer (BC). J Clin Oncol 28(suppl.):Abstract e19561","DOI":"10.1200\/jco.2010.28.15_suppl.e19561"},{"issue":"7","key":"3842_CR52","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1080\/07357900500276899","volume":"23","author":"J Lokich","year":"2005","unstructured":"Lokich J (2005) Same-day pegfilgrastim and chemotherapy. Cancer Investig 23(7):573\u2013576. doi: 10.1080\/07357900500276899","journal-title":"Cancer Investig"},{"issue":"12","key":"3842_CR53","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1007\/s00277-013-1842-x","volume":"92","author":"S Zeynalova","year":"2013","unstructured":"Zeynalova S, Ziepert M, Scholz M, Schirm S, Zwick C, Pfreundschuh M, Loeffler M, German High-Grade Non-Hodgkin Lymphoma Study G (2013) Comparison and modelling of pegylated or unpegylated G-CSF schedules in CHOP-14 regimen of elderly patients with aggressive B-cell lymphoma. Ann Hematol 92(12):1641\u20131652. doi: 10.1007\/s00277-013-1842-x","journal-title":"Ann Hematol"},{"issue":"12","key":"3842_CR54","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1007\/s12094-009-0453-4","volume":"11","author":"R Mattioli","year":"2009","unstructured":"Mattioli R, Gridelli C, Castellanos J, Duque A, Falcone A, Mansutti M, Bacon P, Lawrinson S, Skacel T, Casas A (2009) Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen. Clin Transl Oncol 11(12):842\u2013848","journal-title":"Clin Transl Oncol"},{"issue":"6","key":"3842_CR55","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1097\/JTO.0b013e318060107c","volume":"2","author":"RF Riedel","year":"2007","unstructured":"Riedel RF, Andrews C, Garst J, Dunphy F, Herndon JE 2nd, Blackwell S, Barbour S, Crawford J (2007) A phase II trial of carboplatin\/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer. J Thorac Oncol 2(6):520\u2013525. doi: 10.1097\/JTO.0b013e318060107c","journal-title":"J Thorac Oncol"},{"issue":"1","key":"3842_CR56","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4103\/2278-330X.96494","volume":"1","author":"N Prasad","year":"2012","unstructured":"Prasad N, Bakshi A, Deshmukh C, Hingmire S, Ranade A, Parikh P (2012) Importance of dose intensity in treatment of advanced non-small cell lung cancer in the elderly. South Asian J Cancer 1(1):9\u201315. doi: 10.4103\/2278-330X.96494","journal-title":"South Asian J Cancer"},{"issue":"5","key":"3842_CR57","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/1758834011413423","volume":"3","author":"A Gennari","year":"2011","unstructured":"Gennari A, D'Amico M, Corradengo D (2011) Extending the duration of first-line chemotherapy in metastatic breast cancer: a perspective review. Ther Adv Med Oncol 3(5):229\u2013232. doi: 10.1177\/1758834011413423","journal-title":"Ther Adv Med Oncol"},{"issue":"34","key":"3842_CR58","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1200\/jco.2012.44.6229","volume":"31","author":"MJ Aarts","year":"2013","unstructured":"Aarts MJ, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, van Laarhoven HW, van Warmerdam LJ, van de Wouw AJ, Jacobs EM, Mattijssen V, van der Rijt CC, Smilde TJ, van der Velden AW, Temizkan M, Batman E, Muller EW, van Gastel SM, Borm GF, Tjan-Heijnen VC (2013) Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia. J Clin Oncol 31(34):4290\u20134296. doi: 10.1200\/jco.2012.44.6229","journal-title":"J Clin Oncol"},{"key":"3842_CR59","unstructured":"Roche Products Ltd (2015) Gazyvaro\u00ae summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002799\/WC500171594.pdf . Accessed 30 March 2017"},{"key":"3842_CR60","unstructured":"Takeda Ltd (2016) Adcetris\u00ae summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002455\/WC500135055.pdf . Accessed 30 March 2017"},{"key":"3842_CR61","unstructured":"Celgene Ltd (2015) Revlimid\u00ae summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000717\/WC500056018.pdf . Accessed 30 March 2017"},{"key":"3842_CR62","unstructured":"Janssen-Cilag Ltd (2015) Velcade\u00ae summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000539\/WC500048471.pdf . Accessed 30 March 2017"},{"key":"3842_CR63","unstructured":"Janssen-Cilag Ltd (2015) Imbruvica\u00ae summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003791\/WC500177775.pdf . Accessed 30 March 2017"},{"key":"3842_CR64","unstructured":"Gilead Sciences Ltd (2015) Zydelig\u00ae summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003843\/WC500175377.pdf . Accessed 30 March 2017"},{"issue":"10","key":"3842_CR65","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","volume":"100","author":"E Terpos","year":"2015","unstructured":"Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, van de Donk NW, Bruno B, Sezer O, Broijl A, Bringhen S, Beksac M, Larocca A, Hajek R, Musto P, Johnsen HE, Morabito F, Ludwig H, Cavo M, Einsele H, Sonneveld P, Dimopoulos MA, Palumbo A, European Myeloma N (2015) European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica 100(10):1254\u20131266. doi: 10.3324\/haematol.2014.117176","journal-title":"Haematologica"},{"issue":"1","key":"3842_CR66","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.clml.2011.11.001","volume":"12","author":"A Palumbo","year":"2012","unstructured":"Palumbo A, Blade J, Boccadoro M, Palladino C, Davies F, Dimopoulos M, Dmoszynska A, Einsele H, Moreau P, Sezer O, Spencer A, Sonneveld P, San Miguel J (2012) How to manage neutropenia in multiple myeloma. Clin Lymphoma Myeloma Leuk 12(1):5\u201311. doi: 10.1016\/j.clml.2011.11.001","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"17","key":"3842_CR67","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1182\/blood-2008-07-162842","volume":"113","author":"J Braess","year":"2009","unstructured":"Braess J, Spiekermann K, Staib P, Gruneisen A, Wormann B, Ludwig WD, Serve H, Reichle A, Peceny R, Oruzio D, Schmid C, Schiel X, Hentrich M, Sauerland C, Unterhalt M, Fiegl M, Kern W, Buske C, Bohlander S, Heinecke A, Baurmann H, Beelen DW, Berdel WE, Buchner T, Hiddemann W (2009) Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. Blood 113(17):3903\u20133910. doi: 10.1182\/blood-2008-07-162842","journal-title":"Blood"},{"issue":"3","key":"3842_CR68","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00520-014-2417-7","volume":"23","author":"G Kam","year":"2015","unstructured":"Kam G, Yiu R, Loh Y, Ang AL, Yueh LL, Goh YT, Wong GC (2015) Impact of pegylated filgrastim in comparison to filgrastim for patients with acute myeloid leukaemia (AML) on high-dose cytarabine (HIDAC) consolidation chemotherapy. Support Care Cancer 23(3):643\u2013649. doi: 10.1007\/s00520-014-2417-7","journal-title":"Support Care Cancer"},{"issue":"2","key":"3842_CR69","first-page":"41","volume":"3","author":"A Bosi","year":"2005","unstructured":"Bosi A, Szer J, Kassis J, Siera J, Desborough C, Buchanan K (2005) A multicenter, double-blind, randomized, phase II trial comparing pegfilgrastim with filgrastim as an adjunct to chemotherapy for acute myeloid leukemia. J Support Oncol 3(2):41\u201343","journal-title":"J Support Oncol"},{"key":"3842_CR70","doi-asserted-by":"crossref","unstructured":"Kunivayalil SJ, Jain A, Satheesh C, Tejinder S, Lakshmaiah K, Suresh TM, Lokanatha D, Babu G (2009) A comparative study of single-dose pegfilgrastim versus daily filgrastim in patients with acute myeloid leukemia. J Clin Oncol 27 (suppl; abstr e18005)","DOI":"10.1200\/jco.2009.27.15_suppl.e18005"},{"key":"3842_CR71","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1186\/1471-2407-13-386","volume":"13","author":"I Bondarenko","year":"2013","unstructured":"Bondarenko I, Gladkov OA, Elsaesser R, Buchner A, Bias P (2013) Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin\/docetaxel chemotherapy. BMC Cancer 13:386. doi: 10.1186\/1471-2407-13-386","journal-title":"BMC Cancer"},{"issue":"1","key":"3842_CR72","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10549-014-3120-6","volume":"148","author":"A Buchner","year":"2014","unstructured":"Buchner A, Elsasser R, Bias P (2014) A randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy. Breast Cancer Res Treat 148(1):107\u2013116. doi: 10.1007\/s10549-014-3120-6","journal-title":"Breast Cancer Res Treat"},{"key":"3842_CR73","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s40064-015-1067-7","volume":"4","author":"C Volovat","year":"2015","unstructured":"Volovat C, Bondarenko IM, Gladkov OA, Elsasser R, Buchner A, Bias P, Muller U (2015) Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy. Spring 4:316. doi: 10.1186\/s40064-015-1067-7","journal-title":"Spring"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-017-3842-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-017-3842-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-017-3842-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T19:35:15Z","timestamp":1659382515000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-017-3842-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,25]]},"references-count":73,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["3842"],"URL":"https:\/\/doi.org\/10.1007\/s00520-017-3842-1","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,25]]},"assertion":[{"value":"31 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Aapro received honoraria and\/or consultant fees from Amgen, Bayer, BMS, Celgene, Cephalon, Chugai, Clinigen, Eisai, GenomicHealth, GSK, Helsinn, Hospira, Ipsen, J&J, Kyowa, Merck, Novartis, OrthoBiotech, Pfizer, PierreFabre, Roche, Sandoz, Sanofi, Tesaro, Taiho, Teva, and Vifor. Dr. Boccia consulted for Sandoz GmbH. Professor Leonard consulted for Sandoz GmbH. Professor Camps has nothing to disclose. Professor Campone has nothing to disclose. Professor Choquet consulted for Sandoz GmbH. Professor Danova consulted for Sandoz GmbH. Dr. Glaspy consulted for Sandoz GmbH. Professor Hus received speaker\u2019s fees, travel grants, and\/or acted on advisory boards for Amgen, Celgene, Janssen, Roche, and Sandoz GmbH. Professor Link received research funding and honoraria, acted on speakers\u2019 bureau, and\/or consulted for Amgen, Celgene, Chugai, Lilly, MSD Oncology, Mundipharma, Novartis, Pfizer, Hexal\u2013Sandoz, Teva, and Vifor Pharma. Professor Sliwa consulted for Sandoz GmbH. Professor Tesch received honoraria and\/or consultant fees from Amgen, Sandoz GmBH, Novartis, and Teva. Dr. Valero consulted for Amgen, Sandoz GmbH, and Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}